Oral Semaglutide for Alzheimer's Disease

This study focuses on Alzheimer's disease, a condition that progressively affects the brain, leading to memory loss and cognitive decline. Currently, treatments only address symptoms but do not stop the disease's progression. Researchers are now looking into a medication called Semaglutide, which belongs to a group of drugs known as GLP-1 analogues. These drugs have shown protective effects on brain cells in animal studies. The study aims to explore how Semaglutide might work in humans with Alzheimer's and to assess its safety and how well people can tolerate it. This research is important because it could lead to a treatment that not only alleviates symptoms but also slows down the disease's progression. Participants in the study will take Semaglutide in pill form. Researchers will closely monitor their health to ensure the drug is safe and well-tolerated. To measure the effectiveness of Semaglutide, the study will use a special type of scan called PET to look at the brain before and after treatment. This scan will help determine if there are any changes in synaptic density, which relates to how brain cells communicate with each other. Understanding these changes can provide insights into how the drug might impact Alzheimer's disease, potentially leading to new treatment methods.